TIL Therapy Uses the Body’s Own Cells to Attack Cancer Cells in Melanoma
Source: CureToday, November 2024
Tumor-infiltrating lymphocyte (TIL) therapy is a promising new approach to cancer therapy that harnesses the body’s own immune system to treat diseases like melanoma, a type of skin disease, an expert said.
In February 2024, Amtagvi (lifileucel) was the first FDA-approved TIL therapy to treat patients with advanced melanoma whose disease progressed on or after anti-PD-1/PD-L1 therapy and targeted therapy. With TIL therapy, T cells are extracted from a patient’s tumor, grown in a lab and then reinfused back into the patient to attack cancer cells.
As research progresses, TIL therapy may become a more accessible and effective treatment for other cancers.